Menu
Not yet recruiting NCT07538518

PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels

— Observational Amyloidogenic Transthyretin (ATTR) Amyloidosis Cardiac Amyloidosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Evuzamitide.
Who it may be relevant to
Registry conditions: Amyloidogenic Transthyretin (ATTR) Amyloidosis, Cardiac Amyloidosis. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

TAD1 Risk Assessment for Cardiac Amyloidosis With Evuzamitide (TRACE)

Overview

The goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA) in patients whose standard nuclear imaging results are unclear but who have elevated TAD1 levels in their blood. The main question it aims to answer is: Can evuzamitide PET-CT imaging detect signs of cardiac amyloidosis in patients with non-diagnostic nuclear scintigraphy but elevated TAD1 levels? Participants who meet eligibility criteria will receive a single PET-CT scan with evuzamitide and will be followed for approximately 28 days to monitor safety and collect additional clinical information.

Detailed description

This is a prospective, multicenter observational study designed to evaluate the ability of 124I-evuzamitide PET-CT imaging to resolve the diagnosis of transthyretin cardiac amyloidosis (ATTR-CA) in subjects with discordant findings between nuclear scintigraphy and Transthyretin Amyloid Detector 1 (TAD1) levels.

Up to 25 participants will be enrolled across three sites in the United States, including the University of Texas Southwestern Medical Center, Columbia University Irving Medical Center, and Boston Medical Center. Participants will be selected from clinical registries and prior screening studies and must have non-diagnostic nuclear scintigraphy for ATTR-CA and elevated TAD1 levels.

Eligible participants will receive a single intravenous administration of approximately 1 mCi of 124I-evuzamitide, followed by PET-CT imaging performed approximately 4 hours post-injection. Potassium iodide will be administered before and after imaging to reduce thyroid exposure.

PET-CT images will be evaluated qualitatively and quantitatively for myocardial uptake of the tracer. Image interpretation will be performed by trained physicians, and discrepancies will be resolved by consensus review.

Safety will be assessed through adverse event monitoring, vital signs, and physical examinations, with follow-up conducted approximately 28 days after imaging.

Interventions

  • Drug Evuzamitide
    Eligible participants will receive a single intravenous injection of approximately 1 mCi (±10%) of 124I-evuzamitide (corresponding to \<1.5 mg peptide). PET-CT imaging will be performed approximately 4 ± 1 hours after administration to evaluate myocardial uptake.

Primary outcome measures

  • Number of Participants With Myocardial Uptake of Evuzamitide on PET/CT Imaging [Time frame: At approximately 4 hours (±1 hour) post-injection on Day 1]

Eligibility criteria

Inclusion criteria

  • Diagnosed as having heart failure or TTR variant allele carriers without symptoms of heart failure.
  • Non-diagnostic nuclear scintigraphy for ATTR-CA (Perugini Grade 0 or 1).
  • Elevated levels of Transthyretin Amyloid Detector-1 (TAD1).
  • No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.
  • Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
  • Able to understand and sign the informed consent document after the nature of the study has been fully explained.

Exclusion criteria

  • Primary amyloidosis (AL) or secondary amyloidosis (AA).
  • Ventricular assist device.
  • Disabling dementia or other mental or behavioral disease.
  • Enrollment in a clinical trial not approved for co-enrollment.
  • Continuous intravenous inotropic therapy.
  • Inability or unwillingness to comply with the study requirements.
  • Chronic kidney disease requiring hemodialysis or peritoneal dialysis.
  • Patients taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation.
  • Other reason that would make the subject inappropriate for entry into this study.
  • Pregnancy or current lactational feeding of infants.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 3 centers
  • One Boston Medical Center Place — Boston
  • Columbia University Irving Medical Center — New York
  • Bill and Rita Clements Advanced Medical Imaging Center — Dallas

Identifiers

NCT: NCT07538518 · STU20252574 · 1R01HL177670-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗